Tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta blocker

Clin Pharmacol Ther. 1986 May;39(5):543-9. doi: 10.1038/clpt.1986.93.

Abstract

The tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta-blocker, was investigated in 30 subjects. Flestolol infused intravenously at doses up to 100 micrograms/kg/min was found to be well tolerated. A dose-dependent attenuation of isoproterenol-induced tachycardia and increase in systolic blood pressure occurred with flestolol at doses ranging from 0.5 to 15.0 micrograms/kg/min. The average percent reduction in isoproterenol-induced tachycardia (beta-blockade) at each dose of flestolol, 0.5, 2.5, 5.0, 15.0, and 50.0 micrograms/kg/min, was 15.1%, 45.9%, 67.0%, 85.9%, and 90.3%, respectively. The onset of beta-blockade occurred within 30 minutes. After the end of flestolol infusion there was a marked reduction in beta-blockade within 6 minutes, with complete recovery from beta-blockade within 30 to 45 minutes. There was a statistically significant (P less than 0.01) positive correlation between flestolol dosage and its blood levels (r = 0.91) as well as between the flestolol-induced beta-blockade and its dosage (r = 0.62).

MeSH terms

  • Adult
  • Analysis of Variance
  • Blood Pressure / drug effects
  • Drug Evaluation
  • Fluorobenzenes*
  • Heart Rate / drug effects
  • Humans
  • Infusions, Parenteral
  • Isoproterenol / adverse effects
  • Male
  • Propanolamines / adverse effects
  • Propanolamines / blood
  • Propanolamines / pharmacology*
  • Propanolamines / therapeutic use
  • Tachycardia / chemically induced
  • Tachycardia / drug therapy

Substances

  • Fluorobenzenes
  • Propanolamines
  • Isoproterenol
  • flestolol